The market was valued at approximately $1.3 billion in the base year 2025, and the Plasma Protease C1‑inhibitor Treatment market size is projected to reach $2.3 billion by 2033, reflecting a CAGR of roughly 6.5% over the 2026‑2033 forecast horizon. Growth is propelled by rising prevalence of hereditary angioedema, expanded regulatory approvals for recombinant and gene‑edited C1‑INH products, and improving reimbursement frameworks in mature economies. Key forces shaping the industry include: (1) technological innovation—the shift from plasma‑derived to recombinant and gene‑therapy platforms that enhance safety and dosing convenience; (2) regulatory momentum—accelerated pathways for biosimilars and next‑generation biologics; and (3) supply‑chain resilience—strategic diversification of plasma collection and bioprocessing capacities.
North America remains the largest market, anchored by the United States' robust healthcare infrastructure and early adoption of biologics. Meanwhile, the Asia‑Pacific region is the fastest‑growing, driven by increasing disease awareness, expanding insurance coverage, and local manufacturing initiatives in China, Japan, and South Korea. These dynamics collectively signal a sustained industry expansion and compelling opportunities for strategic entrants and incumbent players alike.
